1,326,614 Shares in Medtronic PLC $MDT Acquired by Magellan Asset Management Ltd

Magellan Asset Management Ltd purchased a new position in shares of Medtronic PLC (NYSE:MDT) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,326,614 shares of the medical technology company’s stock, valued at approximately $126,347,000. Medtronic accounts for about 1.5% of Magellan Asset Management Ltd’s investment portfolio, making the stock its 27th largest position. Magellan Asset Management Ltd owned approximately 0.10% of Medtronic at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Medtronic by 1.5% in the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after acquiring an additional 1,895,165 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Medtronic by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after purchasing an additional 310,684 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Medtronic by 0.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock valued at $2,044,637,000 after purchasing an additional 192,410 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Medtronic by 0.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after purchasing an additional 98,220 shares during the period. Finally, Invesco Ltd. increased its position in Medtronic by 3.9% during the 2nd quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after purchasing an additional 666,557 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Medtronic stock opened at $96.85 on Wednesday. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock has a market cap of $124.16 billion, a P/E ratio of 26.98, a price-to-earnings-growth ratio of 2.48 and a beta of 0.71. The stock has a 50 day moving average of $99.01 and a 200-day moving average of $96.83.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Robert W. Baird reduced their price target on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Sanford C. Bernstein lifted their target price on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Mizuho raised shares of Medtronic to a “strong-buy” rating in a research report on Wednesday, February 18th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Finally, Daiwa Securities Group boosted their price objective on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $110.84.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: MiniMed priced its U.S. IPO at $25–$28 per share (28M shares) targeting about $784M — a clear step toward separating Medtronic’s diabetes business; investors will watch the sale size, Medtronic’s post‑IPO stake and how proceeds are used (value‑unlock thesis). Medtronic’s MiniMed prices IPO at up to $784M
• Positive Sentiment: MiniMed formally launched an IPO roadshow and lists an expected pricing date (investor presentation shows March 5), accelerating the timeline for the separation and potential corporate simplification. MiniMed announces launch of IPO roadshow
• Positive Sentiment: Regulatory/innovation wins: Medtronic secured a CE mark for next‑gen GI Genius module and ColonPRO software — product approvals support durable revenue streams in GI/diagnostics. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Neutral Sentiment: Corporate sustainability and packaging improvements were highlighted in a press release — positive for ESG positioning but unlikely to move near‑term earnings. Improving Sustainability in Packaging & Products
• Neutral Sentiment: Industry and leadership commentary (including former Medtronic CEO Bill George speaking on policy) and trade/tariff debate may affect broader healthcare sentiment but are not direct catalysts for MDT. Trump’s State of the Union: What business leaders want to hear
• Negative Sentiment: Analyst moves: Truist trimmed its price target on MDT (from $107 to $103) while staying at Hold — signaling limited near‑term upside and likely contributing to selling pressure. Medtronic plc (MDT) Gains Momentum Through Diabetes and Cardiovascular Operations
• Negative Sentiment: Market caution: broader market headlines (AI‑job concerns, macro policy uncertainty) have pressured risk assets; with MDT’s spin‑off in play, investors may be trimming positions. Goldman Sachs warns AI-fueled layoffs could raise the unemployment rate this year: Chart

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).